CJC-1295 cycle length: how long to run it and why

Last updated 2026-07-26

What does "cycle length" mean for CJC-1295?

"Cycle length" is a bodybuilding-forum term, not a term you'll find in any peptide's clinical documentation. It means the number of consecutive weeks someone runs a compound before stopping for a break, then usually starting again. For anabolic steroids the idea has some real pharmacology behind it (suppression of natural testosterone production that needs recovery time). For CJC-1295, the concept has been borrowed and applied without the same evidence base. CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue. It was developed to stimulate the pituitary to release its own growth hormone, rather than to replace GH directly. The original research compound, described in a 2005 study in the Journal of Clinical Endocrinology & Metabolism, was engineered with amino acid substitutions and a fatty acid tail (drug affinity complex, or DAC) to resist enzymatic breakdown and extend its half-life ^[1]. Because almost none of the cycling data comes from that original research, and almost all of it comes from anecdote, the honest answer to "how long should a cycle be" is: nobody has run the controlled trial that would tell you. What follows is what the science on the molecule itself can support, and where it stops and folklore starts. For dosing amounts within a cycle, see our CJC-1295 dosage guide. This article is about duration, not amount.

How long do people typically run a CJC-1295 cycle?

The most commonly repeated pattern in peptide-user communities is 8 to 12 weeks on, then 4 to 8 weeks off. Some protocols push to 16 or even 24 weeks continuous use before a break. None of these numbers come from a published human dosing trial that tested cycle length as a variable; they're consensus figures that circulated through forums and have been repeated so often they read as fact. The one number with real data behind it is CJC-1295's half-life, and it depends entirely on which version you mean. | Version | Approximate half-life | Typical injection frequency (community protocols) |

CJC-1295 with DAC vs without DAC: does the difference change cycle length?

CJC-1295 with DAC is the original molecule from the 2005 Teichman study, with a drug affinity complex (a molecule that binds serum albumin) attached to slow clearance. That study found the modified GHRH produced dose-dependent increases in GH and IGF-1 levels lasting up to 6 days after a single injection, and reported the mean half-life at roughly 6.8 days depending on dose ^[1]. "Without DAC" CJC-1295 is a shorter peptide, often labeled Mod GRF (1-29) or tetrasubstituted GRF. It lacks the DAC tail entirely, so its half-life is measured in minutes, not days. It has to be dosed multiple times a day to keep GH pulses going, closely mimicking the body's natural pulsatile GHRH release. This matters for cycle length because the two versions create very different theoretical desensitization risk profiles. Continuous, non-pulsatile receptor stimulation (which is more likely with the long-acting DAC version dosed weekly) has been raised as a concern for pituitary receptor downregulation in commentary on GHRH analogues, though direct long-term human data specific to CJC-1295 cycling is not published. The no-DAC version's short half-life more closely mirrors physiologic GHRH pulses, which is the theoretical argument some peptide users give for preferring it, though this is a mechanistic argument, not a tested outcome. For the full evidence comparison, see CJC-1295 with DAC.

Why do people take breaks between cycles at all?

The rationale rests on a real phenomenon in GH-axis pharmacology: receptor desensitization. When a receptor is stimulated continuously rather than in pulses, the cell can downregulate that receptor's expression or signaling response over time. This is documented for GHRH receptors in animal and in vitro pharmacology literature, and it's the basis for why the body itself releases GHRH in pulses, not a steady drip. What's not documented is whether a specific 8-week or 12-week window is the right cycle length to avoid this in humans using CJC-1295, or whether taking a break actually restores full pituitary responsiveness. Nobody has published that trial. The break period some protocols use (4-8 weeks) appears to be borrowed from anabolic steroid PCT (post-cycle therapy) logic and testosterone suppression recovery timelines, which don't map cleanly onto a GHRH analogue's mechanism. So the honest framing is: taking breaks is a reasonable, biologically plausible precaution given what's known about receptor pulsatility in general. It is not a proven requirement backed by CJC-1295-specific human trial data.

What happens if you run CJC-1295 continuously without a break?

There is no published long-term human safety trial answering this directly. The original 2005 study followed subjects for single-dose and short multi-dose windows, not months of continuous administration ^[1]. Longer-term GH-axis stimulation carries theoretical risks that are worth taking seriously even without CJC-1295-specific data. Sustained elevation of IGF-1 has a documented association with certain cancer risks in epidemiological literature. A pooled analysis published in The Lancet Oncology found that higher circulating IGF-1 concentrations were associated with increased risk of prostate cancer, and similar associations have been studied for breast cancer risk ^[3]. This doesn't mean CJC-1295 causes cancer; it means elevating a growth signal for extended periods is not something to treat casually, and it's a reason clinicians who prescribe GH-axis therapies monitor IGF-1 levels. Other plausible continuous-use concerns, drawn from GH physiology more broadly rather than CJC-1295 trials specifically, include increased insulin resistance and fluid retention, both documented effects of elevated GH/IGF-1 exposure in growth hormone treatment literature from endocrine sources ^[4]. For a full rundown of reported effects, see CJC-1295 side effects. Given the gap between theory and CJC-1295-specific evidence, a cautious approach (defined cycle length, monitoring, breaks) is more defensible than indefinite daily use, even though the specific numbers in most protocols are extrapolated rather than proven.

How is CJC-1295 cycle length different when paired with ipamorelin?

Ipamorelin is a separate compound class entirely: a selective GH secretagogue that acts on the ghrelin receptor (GHS-R), not the GHRH receptor. It's often paired with CJC-1295 because the two act on different receptors in the same GH-release pathway, theoretically producing an additive GH pulse rather than two competing hits on the same receptor. This pairing is popular and mechanistically plausible, but it hasn't been tested together in the kind of controlled trial that would prove the combination outperforms either compound alone in humans, or that it changes optimal cycle length. Most of what's written about "CJC-1295/ipamorelin cycles" running 8-12 weeks comes from the same anecdotal peptide-community sources that generated the CJC-1295-alone protocols, just extended to the stack. If you're using the two together, cycle length recommendations don't functionally change from the CJC-1295-alone numbers above; there's no separate combo-specific trial data suggesting a different window is safer or more effective. What does change is that some users report needing shorter breaks because ipamorelin's ghrelin-receptor action is considered less prone to the same desensitization concern as continuous GHRH stimulation, though again, this is mechanistic reasoning, not a published cycling study.

Does cycle length differ for CJC-1295 with DAC versus the no-DAC (Mod GRF) version?

Yes, and this is one of the more practically important distinctions in the whole topic. Because CJC-1295 with DAC has a multi-day half-life, a single weekly injection keeps blood levels elevated continuously for days at a stretch. That's the version where the desensitization argument for cycling and breaks carries the most theoretical weight, since it's the farthest from natural pulsatile GHRH release. The no-DAC version clears in roughly 30 minutes ^[2], so each dose produces something closer to a discrete pulse, similar in shape (though not necessarily magnitude) to natural GHRH release. Some peptide-community protocols therefore treat the no-DAC version as suitable for longer continuous runs (12+ weeks) without the same theoretical desensitization concern, precisely because it doesn't hold receptors in continuous contact the way the DAC version does. Neither claim has a dedicated human trial testing cycle length as the variable. But the underlying half-life data is real and published, and it's the most defensible reason to treat the two versions differently when planning a schedule.

What does a typical 8 to 12 week protocol actually look like?

Below is a composite of commonly described community protocols, not a clinical recommendation, and not something derived from a controlled dosing trial. It's included so you can see the shape of what's typically discussed, and compare it against what's actually studied. | Element | CJC-1295 with DAC (common pattern) | CJC-1295 no-DAC / Mod GRF (common pattern) |

Is there any regulatory guidance on CJC-1295 dosing or cycling?

No. CJC-1295 is not an FDA-approved drug for any indication. It has no package insert, no approved dosing schedule, and no FDA-sanctioned cycle length. The FDA's compounding oversight addresses this gap somewhat indirectly. Substances have to go through FDA's nomination and review process before they can be used in compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, and that review process itself reflects the regulatory uncertainty around peptides like this one ^[5]. That means anything you read about "how long a cycle should be," including in this article's community-protocol sections above, is not backed by an approved label the way a prescription drug's dosing schedule would be. Growth hormone itself (somatropin) does have FDA-approved dosing for specific diagnosed conditions like GH deficiency, but that approval doesn't extend to CJC-1295 as a GHRH secretagogue for general use ^[6]. If you're sourcing the compound at all, work with a provider that reviews sourcing and pairs you with a pharmacy partner rather than an unregulated seller. CJC-1295 Co's CJC-1295 for sale page explains what a provider-reviewed sourcing route looks like and names the pharmacy fulfilling orders, which is a meaningfully different risk profile than anonymous research-chemical vendors.

How do you know if a cycle is "working" or if you should stop early?

There's no validated biomarker specifically for "CJC-1295 is working, keep going" versus "CJC-1295 has stopped working, stop now." The closest proxy used in both clinical GH-axis monitoring and some peptide-user self-tracking is serum IGF-1, since IGF-1 is the downstream signal GH stimulation is meant to raise, and it's a standard lab clinicians already use to monitor GH-axis activity in diagnosed GH disorders ^[4]. If someone is tracking IGF-1 before, during, and after a cycle, a flattening or decline in IGF-1 despite continued dosing is the pattern that would suggest receptor desensitization is happening, which is the theoretical basis for stopping and taking a break in the first place. Absent lab tracking, most self-reported "end of cycle" decisions in peptide-community writing are based on subjective sleep, recovery, or body-composition impressions, which are useful data points for the individual but aren't objective evidence of receptor status. Any unusual symptom (joint pain, unusual swelling, headaches, vision changes) is a reason to stop and get evaluated, not push through to a planned end date. These are documented reported effects of elevated GH activity in endocrine literature and are not something to wait out ^[4].

Should you stack multiple cycles back to back, or space them out over a year?

Community protocols vary widely here and none of them rest on a controlled long-term trial. Some people run three or four 8-to-12-week cycles per year with breaks between; others run one or two longer cycles. The more conservative pattern, and the one most consistent with the general endocrine principle of avoiding sustained non-pulsatile stimulation, is fewer, well-spaced cycles with real breaks (measured in weeks, not days) rather than back-to-back cycling with minimal gaps. But again: this is a reasoned inference from general GH-axis physiology, not a finding specific to CJC-1295 tested against a control group. If a reader wants the single most defensible position available given the state of the evidence, it's this: treat CJC-1295 cycle length as an unresolved question, pick a conservative, time-limited schedule (8-12 weeks on, meaningful break off), track IGF-1 if possible, and don't extrapolate steroid-cycling logic onto a GHRH analogue just because the word "cycle" is shared.

What's the bottom line on choosing a cycle length?

If you're going to use CJC-1295 at all, the evidence-based facts to anchor your decision are: the DAC version's ~6-8 day half-life supports once-weekly dosing ^[1], the no-DAC version's ~30-minute half-life requires multiple daily doses ^[2], and elevated IGF-1 has documented associations worth monitoring over any extended period ^[3][4]. Everything past that (the specific "8-12 weeks on, 4-8 weeks off" number) is peptide-community convention, not clinical trial output. That doesn't make it wrong, but it does mean you should treat it as a reasonable starting framework, not a proven protocol. Start with the CJC-1295 overview if you haven't already, read the dosage math in CJC-1295 dosage, and check CJC-1295 side effects before deciding on any cycle length at all.

Frequently asked questions

How long should a CJC-1295 cycle last?

There's no FDA-approved answer. Community protocols commonly describe 8 to 12 weeks on followed by 4 to 8 weeks off, based on half-life data and general concerns about receptor desensitization, but no controlled human trial has tested cycle length as a variable for CJC-1295 specifically.

What is the difference between CJC-1295 with DAC and without DAC for cycling purposes?

CJC-1295 with DAC has a roughly 6-8 day half-life and is dosed weekly, keeping levels elevated continuously. No-DAC CJC-1295 (Mod GRF 1-29) has about a 30-minute half-life and needs multiple daily doses to mimic natural GHRH pulses, which changes the theoretical desensitization risk profile between versions.

Do you need a break between CJC-1295 cycles?

Most peptide-community protocols include a 4 to 8 week break, reasoning from general GH-axis receptor desensitization concerns. This isn't proven specifically for CJC-1295 in a human trial, but it's a biologically plausible precaution given how GHRH receptors respond to continuous versus pulsatile stimulation.

Can you take CJC-1295 continuously without cycling off?

No published long-term human trial has tested continuous CJC-1295 use safety. Given documented associations between sustained elevated IGF-1 and certain cancer risk factors reported in pooled epidemiological analyses, most cautious approaches favor defined cycles with breaks over indefinite continuous dosing.

Why is CJC-1295 usually paired with ipamorelin?

Ipamorelin acts on the ghrelin receptor while CJC-1295 acts on the GHRH receptor, so the pairing theoretically produces an additive GH pulse through two separate pathways. This combination hasn't been tested in a dedicated controlled trial proving superior outcomes over either compound alone.

Does pairing with ipamorelin change how long a cycle should be?

Not based on any published data. Cycle length recommendations for the CJC-1295/ipamorelin stack mirror the CJC-1295-alone numbers (8-12 weeks common), since there's no combination-specific trial establishing a different safe or effective duration.

Is CJC-1295 FDA approved, and does that affect dosing guidance?

No. CJC-1295 has no FDA approval and no official dosing label. Substances used in compounding go through FDA nomination and review under Sections 503A/503B of the FD&C Act, and that review process itself reflects regulatory uncertainty rather than an approved use.

How do you know if your CJC-1295 cycle is still working?

There's no validated single marker, but serum IGF-1 tracking is the closest clinical proxy, since it's the standard lab used to monitor GH-axis activity in diagnosed conditions. A flattening IGF-1 despite continued dosing is the pattern some believe reflects receptor desensitization.

What's the difference between a "cycle" for CJC-1295 and one for anabolic steroids?

Steroid cycling addresses testosterone axis suppression and recovery, a well-documented mechanism. CJC-1295 cycling borrows the terminology but addresses a different, less-studied concern (GHRH receptor desensitization from non-pulsatile stimulation), and the specific week-counts haven't been validated the same way.

How often is CJC-1295 with DAC injected during a cycle?

Typically once weekly, based on its roughly 6 to 8 day half-life reported in the original 2005 Journal of Clinical Endocrinology & Metabolism study. This is far less frequent than the no-DAC version, which needs multiple daily injections.

What are the risks of running longer cycles than commonly recommended?

Longer or continuous use raises theoretical concerns about sustained IGF-1 elevation, which has documented associations with insulin resistance and certain cancer risk factors in endocrine and oncology literature. No CJC-1295-specific long-duration human safety trial exists to quantify this risk precisely.

Where can you find dosage amounts to use within a cycle?

The CJC-1295 dosage guide covers microgram and milligram ranges discussed in community protocols, and a dedicated CJC-1295 DAC dosage calculator helps work out weekly amounts based on vial concentration, though neither reflects an FDA-approved dosing standard.

Sources

1. Journal of Clinical Endocrinology & Metabolism, Teichman et al. 2005: CJC-1295 with DAC half-life (~6-8 days) and dose-dependent GH/IGF-1 elevation lasting up to 6 days
2. National Center for Biotechnology Information, PubChem: Short half-life characteristics of GHRH(1-29) analogues without DAC
3. The Lancet Oncology, Roddam et al., Endogenous Hormones and Breast Cancer Collaborative Group pooled analysis (PMID: 19097900): Documented associations between elevated circulating IGF-1 and prostate cancer risk in pooled analysis
4. Endocrine Society, growth hormone clinical practice guideline: Documented effects of elevated GH/IGF-1 including insulin resistance and fluid retention, and IGF-1 as a monitoring marker
5. U.S. Food and Drug Administration, 503A Bulk Drug Substances Nominated for Use in Compounding: CJC-1295 regulatory status under FD&C Act Section 503A/503B compounding review
6. U.S. Food and Drug Administration, Somatropin (growth hormone) label approval: FDA-approved dosing exists for somatropin under diagnosed GH deficiency, unlike CJC-1295